Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

Cites (259)

Items 201–259 of 259

1. Protease bias in absolute protein quantitation
   Peng, Mao, Taouatas, Nadia, Cappadona, Salvatore, van Breukelen, Bas, Mohammed, Shabaz, Scholten, Arjen, Heck, Albert J R · 2012 · Nature Methods
2. Systematic quantification of peptides/proteins in urine using selected reaction monitoring
   Nathalie Selevsek, Mariette Matondo, Marta Sänchez‐Carbayo, Ruedi H. Aebersold, Bruno Domon · 2011 · PROTEOMICS
3. Plasma Exosomes Spread and Cluster Around β-Amyloid Plaques in an Animal Model of Alzheimer’s Disease
   Ting-Ting Zheng, Jia-Li Pu, Yan-Xing Chen, Yan-Fang Mao, Zhangyu Guo, Hong-Yu Pan, Ling Zhang, Heng Zhang, Bing-Gui Sun, Baorong Zhang · 2017 · Frontiers in Aging Neuroscience
4. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease
   Hugo Lövheim, Fredrik Elgh, Anders S. Johansson, Henrik Zetterberg, Kaj Blennow, Göran Hallmans, Sture Eriksson · 2017 · Alzheimer s & Dementia
5. Functional brain imaging in the differential diagnosis of Parkinson's disease
   Paola P. Piccini, Alan L. Whone · 2004 · The Lancet Neurology
6. The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
   Kaj Blennow, Henrik Zetterberg · 2015 · Frontiers in Neuroscience
7. Prediction of Alzheimer's disease in mild cognitive impairment: A prospective study in Taiwan
   P.N. Wang, Jiing Feng Lirng, K.N. Lin, Feng‐Chi Chang, H.C. Liu · 2005 · Neurobiology of Aging
8. Biomarkers in pharmacology and drug discovery
   D.C. Anderson, Krishna Kodukula · 2013 · Biochemical Pharmacology
9. Clinical Criteria for the Diagnosis of Alzheimer Disease: Still Good After All These Years
   Najeeb Ranginwala, Linda Susan Hynan, Myron Weiner, Charles L. White · 2008 · American Journal of Geriatric Psychiatry
10. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid
    Ronald C. Hendrickson, Anita Y. H. Lee, Qinghua Song, Andy I. Liaw, Matt Wiener, Cloud Peter Paweletz, Jeffrey L. Seeburger, Jenny Li, Fanyu Meng, Ekaterina G. Deyanova et al. · 2015 · PLoS ONE
11. Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*
    Min Yan Shi, James Movius, Romel Dator, Patrick Aro, Yanchun Zhao, Catherine Pan, Xiangmin Lin, Theo K. Bammler, Tessandra Stewart, Cyrus P. Zabetian et al. · 2015 · Molecular & Cellular Proteomics
12. Matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry with pulsed in-source collision gas and in-source ion accumulation
    G�khan Baykut, Roland Jertz, Matthias Witt · 2000 · Rapid Communications in Mass Spectrometry
13. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology
    R. Paterson, W. Heywood, A. Heslegrave, N. Magdalinou, U. Andreasson, E. Sirka, E. Bliss, C. Slattery, J. Toombs, J. Svensson et al. · 2016 · Translational Psychiatry
14. Positron emission tomography neuroimaging in Parkinson's disease.
    Clare Loane, Marios Politis · 2011 · PubMed
15. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia
    Stefan Lehnert, Sarah Jesse, Wolfgang Rist, Petra Steinacker, Hilkka S. Soininen, Sanna‐Kaisa Herukka, Hayrettin Tumani, Martin Lenter, Patrick Oeckl, Boris Ferger et al. · 2012 · Experimental Neurology
16. Unbiased False Discovery Rate Estimation for Shotgun Proteomics Based on the Target-Decoy Approach
    Lev I. Levitsky, Mark V. Ivanov, Anna A. Lobas, Mikhail V. Gorshkov · 2016 · Journal of Proteome Research
17. Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
    Mathilde Sauvée, Guerric Didierlaurent, Clotilde Latarche, Marie‐Christine Escanyé, J L Olivier, Catherine Malaplate · 2014 · Journal of Alzheimer s Disease
18. Femtomol sensitivity post‐digest 18 O labeling for relative quantification of differential protein complex composition
    Marcus Bantscheff, Birgit Dümpelfeld, Bernhard Küster · 2004 · Rapid Communications in Mass Spectrometry
19. The role of DNA hypermethylation in human neoplasia
    Minoru Toyota, Jean‐Pierre J. Issa · 2000 · Electrophoresis
20. Monte Carlo Simulations of Tau Proteins: Effect of Phosphorylation
    YongSeok Jho, Ekaterina B. Zhulina, M.W. Kim, Philip A. Pincus · 2010 · Biophysical Journal
21. Imaging Alzheimer's disease pathophysiology with PET
    Lucas Porcello Schilling, Eduardo Rigon Zimmer, Monica Shin, Antoine Leuzy, Tharick Ali Pascoal, Andréa Lessa Benedet, Wyllians Vendramini Borelli, André Palmini, Serge G. Gauthier, Pedro Rosa‐Neto · 2016 · Dementia & Neuropsychologia
22. Moving cancer diagnostics from bench to bedside
    Xuewu Zhang, Lin Li, Dong Wei, Yeeleng Yap, Feng Chen · 2007 · Trends in biotechnology
23. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression
    Begcevic, Ilijana, Tsolaki, Magda, Brinc, Davor, Brown, Marshall, Martinez-Morillo, Eduardo, Lazarou, Ioulietta, Kozori, Mahi, Tagaraki, Fani, Nenopoulou, Stella, Gkioka, Mara et al. · 2018 · F1000Research
24. Protein stability and aggregation in Parkinson's disease
    Philip Alan Robinson · 2008 · Biochemical Journal
25. Simultaneous Determination of Post-Translational Racemization and Isomerization of N-Terminal Amyloid-β in Alzheimer’s Brain Tissues by Covalent Chiral Derivatized Ultraperformance Liquid Chromatography Tandem Mass Spectrometry
    Kōichi Inoue, Daiju Hosaka, Nana Mochizuki, Hiroyasu Akatsu, Kaname Tsutsumiuchi, Yoshio Hashizume, Noriyuki Matsukawa, Takayuki Yamamoto, Toshimasa Toyo’oka · 2013 · Analytical Chemistry
26. Current application of proteomics in biomarker discovery for inflammatory bowel disease
    Patrick PY Chan · 2016 · World Journal of Gastrointestinal Pathophysiology
27. Applying selected reaction monitoring to targeted proteomics
    Enrique Calvo, Emilio Camafeita, Benjamín Fernández‐Gutiérrez, Juan Antonio López · 2011 · Expert Review of Proteomics
28. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson’s Disease
    Ragnhild Eide Skogseth, Kolbjørn Brønnick, Joana B. Pereira, Brit Mollenhauer, Daniel A. Weintraub, Tormod Fladby, Dag Aarsland · 2015 · Journal of Parkinson s Disease
29. Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
    Shanker Swaminathan, Shannon L. Risacher, Karmen K. Yoder, John D. West, Li Shen, Sungeun Kim, Mark H. Inlow, Tatiana Foroud, William Jagust, Robert A. Koeppe et al. · 2013 · Alzheimer s & Dementia
30. The Tau Gene Haplotype H1 Confers a Susceptibility to Parkinson’s Disease
    Jun Zhang, Yiqing Song, Honglei Chen, Dongsheng Fan · 2004 · European Neurology
31. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease
    Tiziana Alberio, Agnese Chiara Pippione, Maurizio Zibetti, Simone Olgiati, Daniela Cecconi, Cristoforo Comi, Leonardo Lopiano, Mauro Fasano · 2012 · Scientific Reports
32. Cerebrospinal fluid biomarkers for Alzheimerʼs disease
    Henrik Zetterberg · 2015 · Current Opinion in Psychiatry
33. Identification of proteins in human substantia nigra
    Efstathia Kitsou, Sheng Pan, JianPeng Zhang, Min Yan Shi, Aram Zabeti, Dennis W. Dickson, Roger L. Albin, Marla Gearing, Daniel T. Kashima, Yan Wang et al. · 2008 · PROTEOMICS - CLINICAL APPLICATIONS
34. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
    Kruse, Niels, Persson, Staffan, Alcolea, Daniel, Bahl, Justyna M.C., Baldeiras, Ines, Capello, Elisabetta, Chiasserini, Davide, Bocchio Chiavetto, Luisella, Emersic, Andreja, Engelborghs, Sebastiaan et al. · 2015 · Neurobiology of Aging
35. Theoretical Impact of Florbetapir (18F) Amyloid Imaging on the Diagnosis of Alzheimer’s Dementia and the Detection of Preclinical Cortical Amyloid
    T. Beach, J. Schneider, L. Sue, G. Serrano, B. Dugger, Sarah E. Monsell, W. Kukull · 2014 · Journal of Neuropathology and Experimental Neurology
36. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease
    Pottiez, Gwënaël, Yang, Li, Stewart, Tessandra, Song, Ning, Aro, Patrick, Galasko, Douglas R., Quinn, Joseph F., Peskind, Elaine R., Shi, Min, Zhang, Jing · 2017 · Journal of Proteome Research
37. Targeted Discovery and Validation of Plasma Biomarkers of Parkinson’s Disease
    Catherine Pan, Yong Feng Zhou, Romel Dator, Carmen Ginghină, Yanchun Zhao, James Movius, Elaine R. Peskind, Cyrus P. Zabetian, Joseph F. Quinn, Douglas Galasko et al. · 2014 · Journal of Proteome Research
38. Mass spectrometry quantification of clusterin in the human brain
    Junjun Chen, Meiyao Wang, Illarion V. Turko · 2012 · Molecular Neurodegeneration
39. MicroRNA Biomarkers in Neurodegenerative Diseases and Emerging Nano-Sensors Technology
    Pratik Shah, Seok Keun Cho, Peter Waaben Thulstrup, Morten Jannik Bjerrum, Phil Hyu Lee, Ju‐Hee Kang, Yong-Joo Bhang, Seong Wook Yang · 2017 · Journal of Movement Disorders
40. Advantageous Uses of Mass Spectrometry for the Quantification of Proteins
    John E. Hale · 2013 · International Journal of Proteomics
41. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
    Craig William Ritchie, Nadja Smailagic, Emma C Ladds, Anna H Noel-Storr, Obioha Chukwunyere Ukoumunne, Steven Martin · 2013 · Cochrane Database of Systematic Reviews
42. Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients
    Han, Sun-Ho, Kim, Jun Seok, Lee, Youngju, Choi, Heesun, Kim, Jong-Won, Na, Duk Lyul, Yang, Eun Gyeong, Yu, Myeong-Hee, Hwang, Daehee, Lee, Cheolju et al. · 2014 · Molecular & Cellular Proteomics
43. Quantification of Amyloid Precursor Protein Isoforms Using Quantification Concatamer Internal Standard
    Junjun Chen, Meiyao Wang, Illarion V. Turko · 2012 · Analytical Chemistry
44. Diagnosis of Alzheimer's Disease in a Community Hospital-Based Brain Bank Program
    Gary Pearl · 1997 · Southern medical journal (Birmingham, Ala. Print)
45. Targeted quantitative analysis of synaptic proteins in Alzheimer’s disease brain
    Rachel Yoon Kyung Chang, Naomi Etheridge, Peter Ronald Dodd, Amanda S. Nouwens · 2014 · Neurochemistry International
46. Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease
    Bor Luen Tang, Rajeev Kumar · 2008 · Annals of the Academy of Medicine Singapore
47. Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson’s disease
    Chun-Na An, Xiaoping Pu, Weizhong Xiao, Hongning Zhang · 2017 · Neuroscience Letters
48. Current Technological Challenges in Biomarker Discovery and Validation
    Peter L. Horvatovich, Rainer Bischoff · 2010 · European Journal of Mass Spectrometry
49. The Personal and Social Consequences of Alzheimer Disease
    David W. Coon, Elizabeth Edgerly · 1999 · Genetic Testing
50. Translational proteomics in Alzheimer's disease and related disorders
    Roberta Ghidoni, Anna Paterlini, Luisa Benussi · 2012 · Clinical Biochemistry
51. An analytical comparison of three immunoassay platforms for subpicomolar detection of protein biomarker GAD65
    Olivier R. Costa, Katrijn Verhaeghen, Sarah Roels, Geert M. Stangé, Zhidong Ling, DANIEL G. PIPELEERS, Frans Gorus, Geert Antoine Martens · 2018 · PLoS ONE
52. Verification of a Parkinson’s Disease Protein Signature in T-Lymphocytes by Multiple Reaction Monitoring
    Tiziana Alberio, Kelly M. McMahon, Manuela Cuccurullo, Lee A. Gethings, Craig Lawless, Maurizio Zibetti, Leonardo Lopiano, Johannes P.C. Vissers, Mauro Fasano · 2014 · Journal of Proteome Research
53. An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression
    Yang Li, Tessandra Stewart, Min Yan Shi, Gwënaël Pottiez, Romel Dator, Rui Wu, Patrick Aro, Robert J. Schuster, Carmen Ginghină, Catherine Pan et al. · 2017 · PROTEOMICS - CLINICAL APPLICATIONS
54. Targeted Mass Spectrometry-Based Approach for Protein–Ligand Binding Analyses in Complex Biological Mixtures Using a Phenacyl Bromide Modification Strategy
    Lorrain Jin, Dongyu Wang, David M. Gooden, Carol H. Ball, Michael C. Fitzgerald · 2016 · Analytical Chemistry
55. Breaking the Bottleneck in the Protein Biomarker Pipeline
    Halina Ewa Witkowska, Steven C. Hall, Susan J. Fisher · 2011 · Clinical Chemistry
56. Labeling Methods in Mass Spectrometry Based Quantitative Proteomics
    Karen A., Jeroen Demmers · 2012 · InTech eBooks
57. Establishment of CD7+ Human Myeloma Sister Cell Lines, KMS-21-PE and KMS-21-BM, Carrying t(11;14) and t(8;14)
    T. Otsuki, H. Wada, N. Nakazawa, M. Taniwaki, Katsunori Kouguchi, M. Ohkura, K. Uehira, K. Isoda, K. Yata, H. Sakaguchi et al. · 2001 · Leukemia and Lymphoma
58. Proteomics of Alzheimer's disease: Unveiling protein dysregulation in complex neuronal systems
    Keith Vosseller · 2007 · PROTEOMICS - CLINICAL APPLICATIONS
59. Alzheimer's Disease: Will Advances Made in the Past Turn the Tide?
    Todd P. Semla · 2007 · Annals of Pharmacotherapy